Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Plasma cell 1Myeloid 1Gastrointestinal 1Breast 1

Conditions

Myeloproliferative Disorders 2Stomach Neoplasms 1Multiple Myeloma 1Lung Neoplasms 1Eosinophilia 1Endometrial Neoplasms 1Cholangiocarcinoma 1Breast Neoplasms 1

Interventions

selinexor 1pemigatinib 1pembrolizumab 1Trastuzumab 1Gemcitabine 1Fentanyl 1Docetaxel 1Cisplatin 1Antineoplastic Protocols 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Endometrial Neoplasms × pemigatinib × Myeloid × Clear all
NCT02393248 2023-01-06

Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)

Incyte Corporation

Phase 1/2 Terminated
201 enrolled 71 charts
BreastGastrointestinalGynecologicMyeloidPlasma cellThoracic

Breast Neoplasms, Lung Neoplasms, Multiple Myeloma, Myeloproliferative Disorders, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡